Michael J. Duffy

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Catharine M. Sturgeon, Michael J. Duffy, Ulf‐Håkan Stenman et al. · Clinical Chemistry · 2008 · 1.1K citations

Medicine, Oncology, Urology +17

Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?

Michael J. Duffy · Clinical Chemistry · 2001 · 802 citations · Full text

Medicine, Oncology, Early Detection +16

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

Maxime P. Look, Wim L.J. van Putten, Michael J. Duffy et al. · JNCI Journal of the National Cancer Institute · 2002 · 604 citations · Full text

Medicine, Biostatistics, Oncology +15

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

Neil A. O’Brien, Brigid C. Browne, Lucy Chow et al. · Molecular Cancer Therapeutics · 2010 · 337 citations

Medicine, Oncology, Pharmacology +17

Proteases as prognostic markers in cancer.

Michael J. Duffy · PubMed · 1996 · 317 citations

Medicine, Oncology, Pathology +16